Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

British Journal of Haematology

Volumn 145, Issue 3, 2009, Pages 344-349

  Habermann, Thomas M ^a   Lossos, Izidore S ^b   Justice, Glen ^c   Vose, Julie M ^d   Wiernik, Peter H ^e   McBride, Kyle ^f   Wride, Kenton ^g   Ervin Haynes, Annette ^g   Takeshita, Kenichi ^g   Pietronigro, Dennis ^g   Zeldis, Jerome B ^g   Tuscano, Joseph M ^h  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Pacific Coast Hematology/Oncology Medical Group   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN CANCER CENTER   (United States)

^f Instat Consulting Inc   (United States)

^g CELGENE CORPORATION   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Efficacy; Lenalidomide; Mantle cell lymphoma; Non Hodgkin lymphoma; Safety

Indexed keywords

ALKALOID; ALKYLATING AGENT; BORTEZOMIB; LENALIDOMIDE; RITUXIMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRONCHOPNEUMONIA; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OSTEOMYELITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SINGLE BLIND PROCEDURE; STAPHYLOCOCCUS INFECTION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEUTROPENIA; RECURRENCE; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 64149112784     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07626.x     Document Type: Article

References (21)

1. Belch, A., Kouroukis, C.T., Crump, M., Sehn, L., Gascoyne, R.D., Klasa, R., Powers, J., Wright, J. Eisenhauer, E.A. (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of Oncology, 18, 116 121.
2. Chanan-Khan, A., Miller, K.C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C.W., Goodrich, D.W., Bernstein, Z.P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P. Czuczman, M.S. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. Journal of Clinical Oncology, 24, 5343 5349.
3. Chang, D.H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S.D., Jagannath, S. Dhodapkar, M.V. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood, 108, 618 621.
4. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244 1253.
5. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210 216.
6. Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B., Knight, R.D. & Multiple Myeloma (010) Study Investigators 2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123 2132.
7. Dredge, K., Marriott, J.B., Macdonald, C.D., Man, H.W., Chen, R., Muller, G.W., Stirling, D. Dalgleish, A.G. (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer, 87, 1166 1172.
8. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 4874.
9. Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundström, C., Langholm, R., Delabie, J., Karjalainen- Lindsberg, M.L., Brown, P., Elonen, E. & Nordic Lymphoma Group 2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687 2693.
10. Haslett, P.A., Hanekom, W.A., Muller, G. Kaplan, G. (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. Journal of Infectious Diseases, 187, 946 955.
11. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943 2950.
12. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J., Knight, R. & Myelodysplastic Syndrome-003 Study Investigators 2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456 1465.
13. Lu, L., Payvandi, F., Wu, L., Zhang, L.H., Hariri, R.J., Man, H.W., Chen, R.S., Muller, G.W., Hughes, C.C., Stirling, D.I., Schafer, P.H. Bartlett, J.B. (2008) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular Research, doi :.
14. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676 684.
15. Ramsay, A.G., Johnson, A.J., Lee, A.M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J.C. Gribben, J.G. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation, 118, 2427 2437.
16. Schafer, P.H., Gandhi, A.K., Loveland, M.A., Chen, R.S., Man, H.W., Schnetkamp, P.P., Wolbring, G., Govinda, S., Corral, L.G., Payvandi, F., Muller, G.W. Stirling, D.I. (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. Journal of Pharmacology and Experimental Therapeutics, 305, 1222 1232.
17. Verhelle, D., Corral, L.G., Wong, K., Mueller, J.H., Moutouh-de Parseval, L., Jensen-Pergakes, K., Schafer, P.H., Chen, R., Glezer, E., Ferguson, G.D., Lopez-Girona, A., Muller, G.W., Brady, H.A. Chan, K.W. (2007) Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Research, 67, 746 755.
18. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B., Knight, R.D. & Multiple Myeloma (009) Study Investigators 2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 2142.
19. Wiernik, P.H., Lossos, I.S., Tuscano, J.M., Justice, G., Vose, J.M., Cole, C.E., Lam, W., McBride, K., Wride, K., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J.B. Habermann, T.M. (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 4952 4957.
20. Witzig, T.E. (2005) Current treatment approaches for mantle-cell lymphoma. Journal of Clinical Oncology, 23, 6409 6414.
21. Witzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P., Ansell, S.M., Luyun, R., Flynn, P.J., Morton, R.F., Dakhil, S.R., Gross, H. Kaufmann, S.H. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology, 23, 5347 5356.